Renal artery stenosis(RAS)is a common disease that endangers human health,usually caused by ath-erosclerosis or fibromuscular dyspalsia.RAS is also one of the most common causes of secondary hypertension,often leading to resistant hypertension with markedly elevated renin levels and early onset of progressive renal insufficiency.In addition,the activation of renin-angiotensin-aldosterone system(RAAS)caused by RAS and pathophysiological changes in-cluding glomerular sclerosis and atrophy,water and sodium retention can also lead to cardiovascular events such as heart failure,pulmonary edema,coronary heart disease and cerebral infarction.Therefore,early recognition of RAS and prompt revascularization in patients with severe stenosis are key to the treatment of RAS.Percutaneous renal artery stenting(PRAS)has become the preferred revascularization for patients with RAS due to its high response rate,minimally invasive-ness,fast recovery and low restenosis rate.However,there are still some unavoidable complications of PRAS,such as aortic dissection,renal artery rupture,puncture vascular aneurysm,contrast allergy and contrast-induced nephropathy.The occurrence of these complications may have adverse consequences for patients,and even death in severe cases.Renal arteriovenous fistula is a very rare complication of PRAS,and clinical experience in its recognition and management is very limited.Few cases that can be collected tend to favor re-surgical intervention.But surgical intervention undoubtedly in-creases the risk of patient suffering and mortality again.Thus,it is of great significance to summarize such complications and give a scientific recommendation to clinicians.This article reports a patient with resistant hypertension who underwent renal arteriography showing severe stenosis of renal vessels and developed a renal arteriovenous fistula after stent implanta-tion.Therefore,it is worth considering whether the renal arteriovenous fistula caused by PRAS should be treated with sur-gical intervention or conservative medical treatment.

Renal artery stenosis(RAS)is a common disease that endangers human health,usually caused by ath-erosclerosis or fibromuscular dyspalsia.RAS is also one of the most common causes of secondary hypertension,often leading to resistant hypertension with markedly elevated renin levels and early onset of progressive renal insufficiency.In addition,the activation of renin-angiotensin-aldosterone system(RAAS)caused by RAS and pathophysiological changes in-cluding glomerular sclerosis and atrophy,water and sodium retention can also lead to cardiovascular events such as heart failure,pulmonary edema,coronary heart disease and cerebral infarction.Therefore,early recognition of RAS and prompt revascularization in patients with severe stenosis are key to the treatment of RAS.Percutaneous renal artery stenting(PRAS)has become the preferred revascularization for patients with RAS due to its high response rate,minimally invasive-ness,fast recovery and low restenosis rate.However,there are still some unavoidable complications of PRAS,such as aortic dissection,renal artery rupture,puncture vascular aneurysm,contrast allergy and contrast-induced nephropathy.The occurrence of these complications may have adverse consequences for patients,and even death in severe cases.Renal arteriovenous fistula is a very rare complication of PRAS,and clinical experience in its recognition and management is very limited.Few cases that can be collected tend to favor re-surgical intervention.But surgical intervention undoubtedly in-creases the risk of patient suffering and mortality again.Thus,it is of great significance to summarize such complications and give a scientific recommendation to clinicians.This article reports a patient with resistant hypertension who underwent renal arteriography showing severe stenosis of renal vessels and developed a renal arteriovenous fistula after stent implanta-tion.Therefore,it is worth considering whether the renal arteriovenous fistula caused by PRAS should be treated with sur-gical intervention or conservative medical treatment.

We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, P = 0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), -46.39 (-86.83 to -5.94) HU; P = 0.025) and day 14 (mean difference (95% CI), -74.21 (-133.35 to -15.08) HU; P = 0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.
COVID-19 ; Humans ; Medicine, Chinese Traditional ; Research ; SARS-CoV-2 ; Treatment Outcome

This study was to determine the correlation between endothelial function and neuro-endocrine-immune (NEI) network through observing the changes of NEI network under the different endothelial dysfunction models. Three endothelial dysfunction models were established in male Wistar rats after exposure to homocysteine (Hcy), high fat diet (HFD) and Hcy+HFD. The results showed that there was endothelial dysfunction in all three models with varying degrees. However, the expression of NEI network was totally different. Interestingly, treatment with simvastatin was able to improve vascular endothelial function and restored the imbalance of the NEI network, observed in the Hcy+HFD group. The results indicated that NEI network may have a strong association with endothelial function, and this relationship can be used to distinguish different risk factors and evaluate drug effects.
Animals ; Diet, High-Fat ; Endocrine System ; Homocysteine ; Humans ; Immune System ; Male ; Nervous System ; Rats* ; Rats, Wistar ; Risk Factors ; Simvastatin